Minimal Residual Disease Clinical Trials

74 clinical trials for Minimal Residual Disease across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• French Assessment of MRD by Liquid Biopsies in Stage III CRC Patients (FRENCH.MRD.CRC) — RECRUITING
• French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM) — RECRUITING
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant — RECRUITING · PHASE1
• MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies — RECRUITING · PHASE2
• To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study) — RECRUITING
• Caris Biorepository Research Protocol — RECRUITING
• French Assessment of MRD by Liquid Biopsies in PDAC Patients (FRENCH.MRD.PDAC) — RECRUITING
• Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil — RECRUITING
• Liquid Biopsy-Based Novel Modality for Postoperative Management of Lung Cancer — RECRUITING · NA
• Infusion of Alloreactive nk Cells for Mrd-positive Aml Patients — RECRUITING · NA
• CtDNA Based MRD Testing for NAC Monitoring in TNBC — RECRUITING
• Better Leukemia Diagnostics Through AI (BELUGA) — RECRUITING
• VA Combined With PD-1 Inhibitor for the Treatment of Relapsed and Refractory AML and High-risk MDS — RECRUITING · PHASE2
• Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not — RECRUITING
• A Study of Chidamide With AZA in MRD Positive AML After Transplant — RECRUITING · NA
• Minimally Residual of Esophageal Cancer 001 — RECRUITING
• Prediction of Postoperative Treatment Efficacy and Recurrence Risk of High-risk GIST Based on Liquid Biopsy MRD — RECRUITING
• A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy — ACTIVE_NOT_RECRUITING · PHASE2
• Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD) — ACTIVE_NOT_RECRUITING · PHASE1
• Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease — ACTIVE_NOT_RECRUITING · PHASE2
• Monitoring MRD in Multiple Myeloma in Serum by Mass Spectrometry — NOT_YET_RECRUITING
• Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome — SUSPENDED · PHASE1
• Study of CD19/CD22 Chimeric Antigen Receptor T Cells in Children & Young Adults w/ Recurrent or Refractory B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Chemotherapy, Total Body Irradiation, and Post-Transplant Cyclophosphamide in Reducing Rates of Graft Versus Host Disease in Patients With Hematologic Malignancies Undergoing Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING · PHASE1
• Integrating Allogeneic NK Cells in High-risk Advanced Stage III-IV Nasopharyngeal Cancer Patients — NOT_YET_RECRUITING · PHASE1
• Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial — NOT_YET_RECRUITING · NA
• Natural Killer(NK) Cell Therapy in Acute Myeloid Leukemia — COMPLETED · PHASE1
• A Study of Local Ablative Therapy (LAT) in People With Non-Small Cell Lung Cancer (NSCLC) — COMPLETED · PHASE2
• Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC — NOT_YET_RECRUITING · NA
• CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells With or Without NKTR-255 in Adults With Recurrent or Refractory B Cell Malignancies — ACTIVE_NOT_RECRUITING · PHASE1
• Blinatumomab in Treating Patients With B-cell Acute Lymphoblastic Leukemia With Minimal Residual Disease — COMPLETED · PHASE2
• Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia and Persistent/Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors — COMPLETED · PHASE1
• Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors — TERMINATED · PHASE1
• Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant — TERMINATED · PHASE1
• Evaluate the Clinical Feasibility of a Novel Neoantigen-Reactive CD8+ T Cell (NART) Detection Technology for Postoperative MRD Surveillance of Pancreatic Cancer — NOT_YET_RECRUITING
• NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL — NOT_YET_RECRUITING · NA
• Natural Killer(NK) Cell Therapy for AML Minimal Residual Disease — TERMINATED · PHASE1
• Development and Application of a Novel Digital Array PCR for Acute Myeloid Leukemia (AML) — TERMINATED
• A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment — OTHER
• Dynamic ctDNA Detection for Colorectal Cancer Liver Metastases — COMPLETED
• Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax — NOT_YET_RECRUITING · NA
• Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022) — NOT_YET_RECRUITING · PHASE3
• ALL SCTped 2012 FORUM Add-on Study Blina Post HSCT — TERMINATED · PHASE2
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma — COMPLETED · PHASE2
• Mobilising Tumour and Immune Cells Via Exercise in Chronic Lymphocytic Leukaemia — COMPLETED · NA
• Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma — WITHDRAWN · PHASE1
• Treatment of MDS/AML Patients With an Impending Hematological Relapse With AZA or ATA and Pevonedistat — COMPLETED · PHASE2
• Predicting the Efficacy and Prognosis of Rectal Cancer Patients Based on ctDNA-MRD Technology — OTHER
• Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies — TERMINATED · PHASE1

Refine this search